About this Research Topic
Tumor immunotherapy is steadily progressing, with different approaches emphasized for different tumors. As experience accumulates, it is important to consider its generality: How might the choice or interpretation of the immunotherapy vary with the tumor type or site?
This Frontiers Topic emphasizes the brain’s place among other tumor sites. Given the brain’s varied tumor types and well-defined anatomical compartments, what is suggested about how the optimal immunotherapy might vary with the tumor type or site? Given what is now known about the immune response to targets in the brain, how well can immunologic findings for the brain and other sites be cross-applied?
Submission is open to all. If you would like to contribute to this topic, please contact the topic editor directly at LoisLampson@hotmail.com.
Suggested topics include:
THE TUMOR: HOW SHOULD IMMUNOTHERAPY VARY WITH THE TUMOR TYPE OR SITE? In each manuscript, the biology of one or more brain tumor types is reviewed. Each author is asked to comment on how the features described might affect the choice or interpretation of immunotherapy.
THE SITE: WHAT CAN WE EXPECT FROM IMMUNOTHERAPY WHEN THE TARGET IS IN THE BRAIN? In each manuscript, an aspect of brain immunology is reviewed. Each author is asked to compare the brain to other sites.
BRAIN TUMOR IMMUNOTHERAPY: WHAT HAVE WE LEARNED SO FAR? Clinical experience with brain tumor immunotherapy, from each author’s center, is reviewed. Authors are asked to give their current perspective: From the past: What might be re-interpreted? In the present: What are the current foci of attention? For the future: What problems or approaches deserve more attention? In general: How does the brain compare to other tumor sites?
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.